Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 132
Selected: 0
NCT IDTitle
NCT05987644Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
NCT03558087Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing
NCT06809140Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
NCT06248606Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
NCT00773474Lonafarnib in Metastatic Breast Cancer
NCT03396471Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary
NCT02101385Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
NCT00890955Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
NCT04589832Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma
NCT04895046Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma
NCT00532441Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
NCT03476174Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma
NCT00860158Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
NCT00216047PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
NCT00732303Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
NCT02365766Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
NCT05903092MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
NCT05852717Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
NCT07471841Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
NCT04541173Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
NCT03737123Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
NCT00216060Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
NCT05467891Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
NCT01034631BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
NCT03502746Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
NCT00235235A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
NCT06728410A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
NCT03501381High Dose IL 2 and Entinostat in RCC
NCT03547999A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC
NCT01215136First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
NCT02586610Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer
NCT07479979Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
NCT03840967A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma
NCT02500121Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer
NCT00522665Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer
NCT05406713Pembrolizumab in Muscle-invasive Bladder Cancer
NCT03451331Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer
NCT01780545Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
NCT01177683Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
NCT07218666Zanzalintinib in Men With Aggressive Variant Prostate Cancer
NCT02549209Pembro/Carbo/Taxol in Endometrial Cancer
NCT02581215Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer
NCT04711824Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
NCT04858256Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
NCT06863311Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
NCT01681433OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
NCT02500901Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)
NCT04886531Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
NCT05251038Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
NCT00572572Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors